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Objectives 
Our economic model predicted long-term best corrected visual acuity (BCVA) in both 
eyes using data from the 100 week LEAVO study, which compared intravitreal 
therapy with ranibizumab, aflibercept and bevacizumab for macular oedema (MO) 
due to central retinal vein occlusion (CRVO). Utilities in LEAVO were collected using 
EuroQol Five Dimension (EQ-5D), EQ-5D with vision bolt-on (EQ-5D-V), and Visual-
Functioning Questionnaire Utility Index (VFQ-UI). We developed mappings to predict 
utilities beyond the study period using better-(BSE) and worse-seeing eye (WSE) 
BCVA, age and sex. 
Methods 
We estimated adjusted-limited dependent variable mixture models with one to four 
components. To predict utility within the components we included BSE BCVA, WSE 
BCVA BSE-WSE BCVA interaction, age and sex as independent variables. We 
considered BSE and WSE BCVA as determinants of component membership. 
Models were compared using the mean error, mean absolute error (MAE), root mean 
square error (RMSE), Akaike information criteria (AIC), Bayesian information criteria 
(BIC) and visual inspection. We plotted predicted versus observed utilities by BSE 
and WSE BCVA and simulated data to compare cumulative distribution functions. 
Results 
For all utility measures, including the BSE-WSE BCVA interaction worsened model 
fit according to BIC. Using BSE and WSE BCVA to predict component membership 
improved model fit. Including more than 1 component consistently improved model 
fit. For each utility measure, the mean error, MAE and RMSE were similar between 
the 2, 3, and 4 component models, but the BIC was lowest for the 2 component 
models for EQ-5D and EQ-5D-V, and for the 3 component model for the VFQ-UI. 
Conclusions 
EQ-5D, EQ-5D-V and VFQ-UI are best predicted using models with multiple 
components in MO due to CRVO. This is consistent with findings from other disease 
areas, and builds on previous research in visual acuity which have been limited to 
ordinary least squares regression. 
 
